RAPID MICRO BIOSYSTEMS, INC. Reports Q3 Loss Below Expectations

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Nov 07 2025

0mins

RPID+5.16%

Should l Buy RPID?

Source: NASDAQ.COM

Third Quarter Loss: RAPID MICRO BIOSYSTEMS, INC. reported a loss of -$11.51 million for the third quarter, which was worse than analysts' expectations of -$0.25 per share.
Revenue Growth: The company's revenue increased by 3.2% to $7.84 million compared to $7.60 million in the same period last year.
Earnings Comparison: The earnings per share remained unchanged at -$0.26, consistent with the previous year.
Full Year Guidance: The company provided a full-year revenue guidance of $33.0 million.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy RPID?" and start using high-conviction signals backed by rigorous historical data.

RPID

$3.87+Infinity%1D

Analyst Views on RPID

Wall Street analysts forecast RPID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPID is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.680

Low

8.00

Averages

8.00

High

8.00

Current: 3.680

Low

8.00

Averages

8.00

High

8.00

Lake Street

NULL -> Buy

initiated

2025-07-28

Reason

Lake Street

Price Target

AI Analysis

2025-07-28

initiated

NULL -> Buy

Reason

Lake Street initiated coverage of Rapid Micro Biosystems with a Buy rating and $8 price target. Rapid is \"emerging as the category leader\" in microbial quality control automation with its Growth Direct platform, says the analyst, who believes the market has yet to fully appreciate the already existing scale and growing adoption of Growth Direct. The firm sees further upside as recurring revenue continues to scale given \"the stickiness of the platform,\" the analyst added.

Keybanc

Paul Knight

Buy

Initiates

2025-02-12

Reason

Keybanc

Paul Knight

Price Target

2025-02-12

Initiates

Buy

Reason

KeyBanc initiated coverage of Rapid Micro Biosystems with an Overweight rating and $8 price target. The analyst believes Rapid Micro's Microbial Growth Direct System is "changing the paradigm" in biological manufacturing quality control. The system is more accurate and provides digital results in three to five days versus manual methods in 5-14 days, the analyst tells investors in a research note. KeyBanc says Rapid Micro is gaining wide adoption in the biopharmaceutical industry that will increase sales visibility and improve margins.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RPID

Unlock Now

About RPID

Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%

Jan 14 2026NASDAQ.COM

Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.

Rapid Micro Biosystems (RPID) Reports Q4 Revenue of $11.3M, Raises 2025 Guidance to $33M

Jan 14 2026seekingalpha

Quarterly Revenue Growth: Rapid Micro Biosystems reported approximately $11.3 million in revenue for Q4, indicating sustained growth and strong market demand in the biosystems sector.
Recurring Revenue Increase: The expected recurring revenue for Q4 2025 is approximately $4.6 million, representing a 10% growth compared to the prior-year period, reflecting steady improvements in customer base and product demand.
Guidance Upgrade: Rapid Micro Biosystems raised its 2025 revenue guidance to at least $33 million, demonstrating the company's confidence in future performance and ongoing market demand.
Surge in Multi-System Orders: The company secured a record number of multi-system orders during the reporting period, driving revenue growth and accelerating margin improvement, showcasing its competitiveness and enhanced market position.

Rapid Micro Biosystems (RPID) Projects 2025 Revenue of $33.6 Million, Up 20%

Jan 14 2026seekingalpha

Quarterly Revenue Expectation: Rapid Micro Biosystems anticipates preliminary unaudited fourth-quarter 2025 revenue of approximately $11.3 million, reflecting a robust 37% year-over-year growth that underscores the company's strong performance in the life sciences technology sector.
Full-Year Revenue Outlook: The company projects full-year 2025 revenue to be around $33.6 million, representing a year-on-year growth of about 20%, indicating sustained demand for its products and increasing market recognition.
Recurring Revenue Growth: Expected recurring revenue for the fourth quarter is $4.6 million, while full-year recurring revenue is forecasted at $17.8 million, showcasing the company's solid performance in establishing stable revenue streams.
Future Guidance: Rapid Micro Biosystems plans to release full audited results and its 2026 outlook in the first quarter, further enhancing investor confidence in the company's future growth trajectory.

Highlights from Rapid Micro Biosystems Inc (RPID) Q3 2025 Earnings Call: Record Revenue Achieved

Nov 08 2025Yahoo Finance

Third Quarter Financial Performance: Rapid Micro Biosystems Inc reported Q3 revenue of $7.8 million, with consumables revenue up 40% and service revenue increasing by 12%, contributing to a 30% year-over-year rise in recurring revenue.
Record Multi-System Order: The company secured a significant multi-system order from a top biopharma customer, indicating strong commercial momentum, although they anticipate a temporary decrease in service revenue in Q4.
Collaboration and Margin Outlook: Progress with Millipore Sigma is expected to enhance margins starting in the second half of 2026, despite current product margins being slightly negative.
Future Expectations: The company expects onshoring to positively impact business in 2027 and beyond, while gross margins for Q4 are projected to be in the mid-single digits due to ongoing profitability challenges.